article thumbnail

Researchers Identify Chemotherapy Resistance Biomarkers in Triple-Negative Breast Cancer

Pharmacy Times

DNA and RNA sequencing could provide insight about resistance to chemotherapy in patients suffering from triple-negative breast cancer.

article thumbnail

A gene test could guide decisions around chemotherapy for bowel cancer

Pharmafile

Scientists from the Institute of Cancer Research London, Imperial College London and the Netherlands Cancer Institute have researched a gene test which can select which advanced bowel cancer patients will respond the best to chemotherapy.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Two-dose chemotherapy drug enters clinical trial for cancer patients

Pharmafile

South Korean biotech firm Hyundai Bioscience’s innovative chemotherapy drug may be able to complete cancer treatments in two doses. The new anticancer drug, Polytaxel, is set to enter a clinical trial on pancreatic cancer being held in Australia. read more. Research and Development

article thumbnail

Trilaciclib Protects Against Chemotherapy-Induced Myelosuppression

Pharmacy Times

Treatment's approval marks exciting new development for patients with ES-SCLC to prevent CIM.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.

article thumbnail

A study to avoid chemotherapy in patients with early HER-2+ breast cancer

Pharma Phorum

The PHERGain II study’s goal is to find an effective therapeutic strategy that can reduce the use of chemotherapy and improve the quality of life of patients without compromising the clinical effectiveness of their treatment.

article thumbnail

EC approves Regeneron’s Libtayo along with chemotherapy for NSCLC

Pharmaceutical Technology

The European Commission (EC) has granted approval for Regeneron Pharmaceuticals’ Libtayo (cemiplimab), along with platinum-based chemotherapy, as the first-line treatment for PD-L1 expression positive advanced non-small cell lung cancer (NSCLC) in adult patients.

article thumbnail

Fennec finally pushes drug to prevent chemotherapy-induced hearing loss across the FDA finish line

Fierce Pharma

Fennec finally pushes drug to prevent chemotherapy-induced hearing loss across the FDA finish line. esagonowsky. Wed, 09/21/2022 - 09:58

article thumbnail

Adding veliparib to chemotherapy can extend progression-free survival in in some breast cancer patients

Pharmafile

It appears that adding veliparib to chemotherapy can extend progression-free survival (PFS) in patients suffering from triple negative breast cancer (TNBC) with a ‘BRCA-like’ phenotype.

article thumbnail

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy

Pharma Mirror

The post The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy appeared first on Pharma Mirror Magazine.

article thumbnail

FDA Approves Libtayo, Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer

Pharmacy Times

Efficacy results comparing the cemiplimab-rwlc combination to chemotherapy alone showed a 22-month median overall survival versus 13 months.

article thumbnail

FDA approves Regeneron’s Libtayo and chemotherapy combination for NSCLC

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals ’ PD-1 inhibitor Libtayo (cemiplimab-rwlc) and chemotherapy combination as the first-line treatment for advanced non-small cell lung cancer (NSCLC).

article thumbnail

Opdivo and chemotherapy combo increases survival in lung cancer patients

Pharma Phorum

Lung cancer drug Opdivo administered with chemotherapy has been shown to boost survival rates in patients with resectable non-small cell lung cancer (NSCLC). The post Opdivo and chemotherapy combo increases survival in lung cancer patients appeared first on.

article thumbnail

FDA Approves Tremelimumab Plus Durvalumab With Chemotherapy for Metastatic Non-Small Cell Lung Cancer

Pharmacy Times

Tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy approved for the treatment of adults with metastatic non–small cell lung cancer without sensitizing EGFR mutation or ALK aberrations.

article thumbnail

Durvalumab Plus Chemotherapy Approved as First Immunotherapy Regimen for Treatment of Advanced Biliary Tract Cancer

Pharmacy Times

Results from the TOPAZ-1 phase 3 trial showed that the combination reduced risk of death by 20% versus chemotherapy alone.

article thumbnail

Dostarlimab Plus Chemotherapy Shows Promise in Non-Small Cell Lung Cancer

Pharmacy Times

Results from the largest head-to-head trial of programmed death receptor-1 inhibitors suggest that dostarlimab and chemotherapy could be an effective treatment option for patients with metastatic non-squamous non-small cell lung cancer.

article thumbnail

Innovation in chemotherapy: Leading companies in platinum-based cancer drug compositions

Pharmaceutical Technology

Platinum-based cancer drug compositions is a key innovation area in chemotherapy Platinum-based drugs are chemotherapeutic agents used for the treatment of cancer.

article thumbnail

Innovation in chemotherapy: Leading companies in purine derivatives-based cancer drug compositions

Pharmaceutical Technology

Purine derivatives-based cancer drug compositions is a key innovation area in chemotherapy Purine is an important heterocyclic nucleus in the chemical architecture of many bioactive compounds.

article thumbnail

Clinical Overview: The Addition of Curcumin to Standard Ovarian Cancer Chemotherapy

Pharmacy Times

For the management of ovarian cancer, it has been observed in both cellular and animal models that curcumin suppresses cell proliferation and promotes apoptosis.

article thumbnail

Phase 3 Trial Showed Pembrolizumab in Combination With Chemotherapy Had Statistically Significant Improvement in Overall Survival in HER2-Negative Gastric, Gastroesophageal Junction Adenocarcinoma

Pharmacy Times

The trial data demonstrated that pembrolizumab in combination with chemotherapy also had statistically significant and clinically meaningful improvements in PFS and ORR as well.

article thumbnail

Trastuzumab Deruxtecan Bests Chemotherapy-Based Regimens in Those Previously Treated With T-DM1

Pharmacy Times

DESTINY-Breast02 clinical trial results show trastuzumab deruxtecan demonstrated a clinically meaningful and statistically significant improvement in progression-free and overall survival.

article thumbnail

The end-of-life care conundrum

Pharma Phorum

Over recent years, there has been a growing consensus that using chemotherapy and aggressive treatments towards the end-of-life should be avoided, where possible, due to the lower quality of life reported.

article thumbnail

Imfinzi Plus Chemotherapy Shows Positive Results for Advanced Biliary Tract Cancer

Pharmacy Times

Phase 3 TOPAZ-1 trial of AstraZeneca’s durvalumab demonstrates an improved overall survival benefit.

article thumbnail

Afternoon Chemotherapy Found to Improve Treatment Outcomes in Women With Lymphoma

Pharmacy Times

Chronochemotherapy aims to time drug delivery when the body is the least vulnerable to harmful effects, while the cancer cells are the most vulnerable.

article thumbnail

Pembrolizumab Plus Chemotherapy Significantly Improves Overall Survival in First-Line Advanced, Unresectable Biliary Tract Cancer

Pharmacy Times

Specific data and results for pembrolizumab in patients with advanced or unresectable biliary tract cancer will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.

article thumbnail

Sacituzumab Govitecan-hziy Significantly Improves Overall Survival in HR+/HER2- Metastatic Breast Cancer vs Chemotherapy

Pharmacy Times

Gilead Sciences Inc submitted a supplemental Biologics License Application to the FDA for sacituzumab govitecan-hziy (Trodelvy) following promising trial results.

article thumbnail

Chemotherapy May Eliminate Need for Allogeneic Stem Cell Transplant for Newly Diagnosed Patients with ALL, Relapsed/Refractory ALL

Pharmacy Times

Currently available agents may reduce the need for stem cell transplantation in patients with acute lymphocytic leukemia.

article thumbnail

A history of blood cancer treatment

Pharma Phorum

While they may not have known it at the time, through their work Ehrlich and Metschnikow formed the cornerstone of modern immunology, including chemoreceptor and chemotherapy concepts that revolutionised blood cancer treatment over the following century.

article thumbnail

Avacta gets MHRA green-light to start phase I trial for ‘pro-drug’ chemotherapy

Pharma Times

AVA6000 is pro-drug form of the chemotherapy doxorubicin, modified using Avacta's pre|CISION chemistry

article thumbnail

NICE recommends MSD’s Keytruda in combination with chemotherapy for routine treatment of lung cancer

Pharma Times

With over 48,000 new cases diagnosed per year, lung cancer is the third most common cancer in the UK

article thumbnail

Be in the room: Turning patient engagement to patient centricity

Pharma Phorum

Robert decided to enrol on a clinical trial of chemotherapy plus high dose vitamin D at the University of Pennsylvania. Oncology Patients Views & Analysis Views and analysis cancer chemotherapy patient voices

article thumbnail

DuPont Announces Research Collaboration with Rutgers University

Pharma Mirror

The two-year research partnership will focus on improving the benefit/risk ratio of chemotherapy by decreasing gut inflammation caused by chemotherapy to potentially improve response rates through modulation. Pharmaceutical News Chemotherapy Collaboration DuPont Rutgers University

article thumbnail

Phase 3 lung cancer fail dents prospects of Ipsen, Servier’s Onivyde

Pharma Phorum

Ipsen and Servier’s hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a failed phase 3 trial of the drug as a second-line therapy for small cell lung cancer (SCLC). News Oncology R&D chemotherapy Ipsen Onivyde Servier small cell lung cancer

article thumbnail

Immunotherapy Makes Major Strides for First-line Treatment of Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Pharmacy Times

Specific immune checkpoint inhibitors added to frontline chemotherapy have transformed modern clinical practice.

article thumbnail

ICR urges change as NICE rejects Keytruda plus chemotherapy

Pharma Times

Keytruda backed for monotherapy treatment but combination therapy rejected

article thumbnail

BeyondSpring faces a tough winter as FDA rejects its lead drug

Pharma Phorum

BeyondSpring’s hopes of an early Christmas gift from the FDA were dashed today after the regulator said it was unable to approve the company’s lead drug plinabulin as a treatment for low white blood cell counts caused by cancer chemotherapy.

article thumbnail

GSK shares promising clinical trial results for endometrial cancer therapy

Pharmafile

GSK has announced promising results from part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial for Jemperli (dostarlimab) alongside standard-of-care chemotherapy (carboplatin-paclitaxel) followed by dostarlimab, compared to chemotherapy and a placebo, in adult patients with primary advanced or recurrent endometrial cancer.

article thumbnail

Pembrolizumab Shows Promise in NSCLC, Breast Cancer

Pharmacy Times

When used with chemotherapy, pembrolizumab provides a synergistic response to increase survival rates.

article thumbnail

FDA Approves First Therapy for New HER2-low Breast Cancer Subtype

Pharmacy Times

The FDA approved a new drug that treats unresectable and metastatic HER2-low breast cancer, giving patients with this new subtype a treatment beyond chemotherapy.

article thumbnail

Durvalumab Improves Event-Free Survival in Resectable Non–Small Cell Lung Cancer

Pharmacy Times

Adding durvalumab to neoadjuvant chemotherapy to treat resectable early-stage non–small cell lung cancer did not increase complications and adverse events or comprise patients’ ability to undergo surgery versus chemotherapy alone.

article thumbnail

Interim FDG-PET/CT May Have Positive Prognostic Value for Hodgkin’s Lymphoma

Pharmacy Times

Research suggests that positron emission tomography scans are effective at detecting early and late Hodgkin’s lymphoma, and the results could help manage and reduce toxicity from current chemotherapies.

article thumbnail

Expert Suggests Having a Risk Assessment of VEGF Inhibitor-Related Cardiovascular Toxicity

Pharmacy Times

It may be worth considering the pathophysiology and vascular complications of chemotherapy, especially among patients who are already hypertensive.

article thumbnail

EMA accepts BMS’ Opdivo application in oesophageal cancer

Pharma Times

Phase III trial showed significant survival benefit over chemotherapy alone